Abstract: A method is disclosed for 3D printing of soft polymeric material such as a hydrogel or elastomer for scaffolds or devices with embedded channels with tunable shape and size such as a channel inner diameter). The method utilizes extrusion based printing of polymer solutions usually referred as direct ink writing (DIW) or BioPlotting, and requires sequential printing of a photocurable polymer solution, herein, referred as the matrix material, and a sacrificial polymer solution that may dissolve in an aqueous media.

Abstract: Disclosed is a new 3D bioprinting method of soft polymeric material such as a hydrogel or elastomer and/or cells for scaffolds or devices with structures. The method utilizes in one aspect extrusion based printing of polymer solutions, hydrogels and cells referred as direct ink writing (DIW) or BioPlotting that is modified to offer break-through advantages. The method may utilize sequential printing of a photocurable polymer solution or matrix material, and a functional hydrogel and/or cells. Printing within or inside of a viscous non-cured layer is accomplished by printing cells directly into the functional hydrogel. The viscous layer does not need to be shear thinning and thus allows use of a wide variety of bioinks never before allowed because of shear thinning and recovery requirement of commonly utilized extrusion based embedded bioprinting approach. Complex printing patterns never before allowed for bioinks are now possible utilizing this new printing method.

Abstract: A compound dispersant which is composed of distilled water, a nonionic surfactant, an anionic surfactant and a wetting agent. The nonionic surfactant is a Tween compound, and the anionic surfactant is hydrocarbyl sulfate salts. The compound dispersant can block or slow down agglomeration of graphene in a dispersion solution. Also disclosed are a preparation method of the compound dispersant, which is simple to operate, a mixed electroplating solution containing the compound dispersant, in which the graphene is dispersed uniformly and stably, and a preparation method of the mixed electroplating solution, in which graphene is distributed uniformly and stably.

Abstract: A compound dispersant which is composed of distilled water, a nonionic surfactant, an anionic surfactant and a wetting agent. The nonionic surfactant is a Tween compound, the anionic surfactant is a hydrocarbyl sulfonate salt compound, and the wetting agent is an amide compound. The compound dispersant can block or slow down agglomeration of graphene in a dispersion solution. In addition, disclosed are a preparation method of the compound dispersant, which is used for preparing the compound dispersant and is simple to operate, a mixed electroplating solution containing the compound dispersant, in which the graphene is dispersed uniformly and stably, and a preparation method of the mixed electroplating solution, in which graphene is distributed uniformly and stably.

Abstract: A compound dispersant which is composed of distilled water, a nonionic surfactant, an anionic surfactant and a wetting agent, wherein the nonionic surfactant is a Tween compound, and the wetting agent includes a hydrocarbyl sulfate salt compound and a hydrocarbyl sulfonate salt compound. The compound dispersant can block or slow down agglomeration of graphene in a dispersion solution. Also disclosed are preparation method of the compound dispersant, which is simple to operate and produces a compound dispersant that can effectively block or slow down the agglomeration of graphene in the dispersion solution, a mixed electroplating solution including the compound dispersant, in which the graphene is dispersed uniformly and stably, and a preparation method of the mixed electroplating solution, which is simple to operate, wherein graphene is distributed uniformly and stably.

Abstract: Disclosed is a new 3D bioprinting method of soft polymeric material such as a hydrogel or elastomer and/or cells for scaffolds or devices with structures. The method utilizes in one aspect extrusion based printing of polymer solutions, hydrogels and cells referred as direct ink writing (DIW) or BioPlotting that is modified to offer break-through advantages. The method may utilize sequential printing of a photocurable polymer solution or matrix material, and a functional hydrogel and/or cells. Printing within or inside of a viscous non-cured layer is accomplished by printing cells directly into the functional hydrogel. The viscous layer does not need to be shear thinning and thus allows use of a wide variety of bioinks never before allowed because of shear thinning and recovery requirement of commonly utilized extrusion based embedded bioprinting approach. Complex printing patterns never before allowed for bioinks are now possible utilizing this new printing method.

Abstract: A method is disclosed for 3D printing of soft polymeric material such as a hydrogel or elastomer for scaffolds or devices with embedded channels with tunable shape and size such as a channel inner diameter). The method utilizes extrusion based printing of polymer solutions usually referred as direct ink writing (DIW) or BioPlotting, and requires sequential printing of a photocurable polymer solution, herein, referred as the matrix material, and a sacrificial polymer solution that may dissolve in an aqueous media.

Abstract: A method is disclosed for 3D printing of soft polymeric material such as a hydrogel or elastomer for scaffolds or devices with embedded channels with tunable shape and size such as a channel inner diameter). The method utilizes extrusion based printing of polymer solutions usually referred as direct ink writing (DIW) or BioPlotting, and requires sequential printing of a photocurable polymer solution, herein, referred as the matrix material, and a sacrificial polymer solution that may dissolve in an aqueous media.

Abstract: Disclosed is a new 3D bioprinting method of soft polymeric material such as a hydrogel or elastomer and/or cells for scaffolds or devices with structures. The method utilizes in one aspect extrusion based printing of polymer solutions, hydrogels and cells referred as direct ink writing (DIW) or BioPlotting that is modified to offer break-through advantages. The method may utilize sequential printing of a photocurable polymer solution or matrix material, and a functional hydrogel and/or cells. Printing within or inside of a viscous non-cured layer is accomplished by printing cells directly into the functional hydrogel. The viscous layer does not need to be shear thinning and thus allows use of a wide variety of bioinks never before allowed because of shear thinning and recovery requirement of commonly utilized extrusion based embedded bioprinting approach. Complex printing patterns never before allowed for bioinks are now possible utilizing this new printing method.

Abstract: A method is disclosed for 3D printing of soft polymeric material such as a hydrogel or elastomer for scaffolds or devices with embedded channels with tunable shape and size such as a channel inner diameter). The method utilizes extrusion based printing of polymer solutions usually referred as direct ink writing (DIW) or BioPlotting, and requires sequential printing of a photocurable polymer solution, herein, referred as the matrix material, and a sacrificial polymer solution that may dissolve in an aqueous media.

Abstract: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.

Abstract: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.

Abstract: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.

Abstract: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.

Abstract: Ammeline-melamine-formaldehyde resins (AMFR) containing from 5-100% ammeline were synthesized by the polymerization of the sodium salt of ammeline, which must be made in advance, melamine, and formaldehyde in basic medium (pH=9.2-10.0). In this copolymerization, it is possible to make uniform random AMFR resins with any mole ratio of ammeline salt to melamine. Preferably the AMFR resin will contain from 5-10% ammeline. As an "ionomer" or a "polyelectrolyte," both the solid and solution properties of these resins (such as melting temperature, solubility, solution stability, etc.) depended directly on the mole ratio of ammeline to melamine and formaldehyde, and/or on the pH value of the medium in which the AMFR resin was present. The pH value controlled the ammeline rings/ammeline's salt groups and also the ratio of unprotonated to protonated amino groups on both the melamine and ammeline rings.

Abstract: A process of producing melamine formaldehyde resins using crude or impure melamine is described. The process using the impure or crude melamine includes the control of the pH within the range of from about 8 to 10, and preferably 9 to 9.2 during at least the initial stages of the formaldehyde/melamine reaction. The pH control provides resins having commercially acceptable characteristics, with the cook times of the resin formation also being commercially acceptable.